Novo Nordisk and Orbis Medicine launched a drug discovery partnership valued at up to $1.4 billion. The collaboration focuses on developing new treatments for cardiometabolic diseases.
The project utilizes Orbis’s nGen AI platform to develop oral macrocycle treatments. Novo Nordisk will make a strategic investment in the Copenhagen-based biotech firm. Orbis receives an upfront payment and remains eligible for development and commercial milestones. The agreement also includes tiered royalties on future product sales.
The deal highlights the growing role of artificial intelligence in accelerating drug development. Novo Nordisk aims to create a new generation of oral therapies for metabolic and heart conditions. This partnership strengthens the company's existing dominance in the cardiometabolic market.